Chartwell Governmental & Specialty RX, LLC. announced the approval of its generic acyclovir ANDA (app# ANDA212718), which significantly broadens market accessibility for this antiviral drug amid sustained demand. This regulatory milestone is anticipated to intensify competitive pressure and drive immediate cost savings for payers following the potential expiration of multiple brand exclusivity periods.